IP Verse

Cancer Treatments - EP3197456

The patent EP3197456 was granted to Nucana on Oct 11, 2023. The application was originally filed on May 14, 2015 under application number EP15726258A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3197456

NUCANA
Application Number
EP15726258A
Filing Date
May 14, 2015
Status
Patent Maintained As Amended
Sep 8, 2023
Grant Date
Oct 11, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MULLENDec 20, 2018ELKINGTON AND FIFE -

Patent Citations (3) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2005012327
INTERNATIONAL-SEARCH-REPORTWO2009036099
OPPOSITIONWO2009036099

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ""Cancer Stem Celts", MACS- Milterryi Biotec: ''Cancer Stem Celts, (20080000), URL: https://millenyibiotec.com/media/Images/Products/Import/ 0001700/IM0001 784. ashx, (20151102), XP002750006-
OPPOSITION- GHAZALY et al., "Acelarin: A novel nucleotide analogue that overcomes the key cancer resistance mechanisms with poor survival", Acelarin: A novel nucleotide analogue that overcomes the key cancer resistance mechanisms with poor survival, (20140000), URL: http://www. nucanabiomed. com/downloads/ Nucana2014AACRPoster.pdf, (20151102), XP002750004-
OPPOSITION- GHAZALY et al., ProGem1: A phase |7|| study of a first-in-class nucleotide analogue Acelarin (NUC-1031) In patleins with advances solid tumor, (20140000), URL: URL///www.nucanablomed.com/downloads/ Nucana2014ASCOPoster.pdf, (20151102), XP002750002-
OPPOSITION- Li et al. -"Pancreatic cancer stem cells: Emerging target tor designing novel therapy Cancer Letters 338 (2013) 94-100-
OPPOSITION- MCGUIGAN, "A phosphoramidate Pro Tide (NUC-1031) and acquired and intrinsic ressitaroce to gemcitabine", J. Clin. Oncol, vol. 29, page E13540,2011, URL: http://metiniglibrary.asco.org/print/571553, (20151102), XP002750003-
OPPOSITION- V.A. VENKATASUBBAIAH et al., "Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition", Neoplasia, (20120000), vol. 14, no. 6, pages 519 - 525-
OPPOSITION- V.A. VENKATASUBBAIAH et al., "Sensitization of Pancreatic Cancer Stem Cells to Gemcitabine by Chk1 Inhibition", Neoplasia, (20120000), vol. 14, no. 6, pages 519 - 525, XP055548680-
OPPOSITION- SHE MTAORONG et al., "Resistance of leukemic stem-like cells in AML cell line KG 1a to natural killer cell -modiatod cytotoxicity", CANCER LETTERS, (20120528), vol. 318, no. 2, ISSN 1872-7980, pages 173 - 179, XP002750007
OPPOSITION- SLUSARCZYK, "Application of ProTide Technology to Gemcitahlne: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUG-liD31) in Clinical Development", J- MED. CHEM, (20140000), vol. 57, pages 1531 - 1542, XP055205033

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents